



Republic of the Philippines
DEPARTMENT OF HEALTH
OFFICE OF THE SECRETARY

21 January 2015

CERTIFICATION


This is to certify the provisional exemption for one year, effective upon receipt of this certificate, of the following medicine:

Medicine: **Triflusal 300 mg capsule**

Indication: For secondary prevention after a first coronary or cerebrovascular ischemic event of myocardial infarction, stable and unstable angina, non-hemorrhagic stroke or transient ischemic attack and reduction of vein graft occlusion after coronary bypass.

The product shall only be utilized by the requesting party – the Veterans Memorial Medical Center, and the concerned proponent shall provide to the Formulary Executive Council (FEC) through the National Center for Pharmaceutical Access and Management (NCPAM) the following: (1) local safety profile; (2) surveillance report on adverse effects; and (3) impact study/outcomes of patients using the product. These shall be submitted after expiration of the validity.

For compliance and strict implementation.


ANNA MELISSA S. GUERRERO, MD, MPH (HTA)
OIC, Program Manager
National Center for Pharmaceutical Access and Management